[PRNewswire] Debiopharm Encourages Breakthrough Cancer Research in Japan
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Through its Competitive JCA Mauvernay Award
(LAUSANNE, Switzerland, Oct. 4, 2021 PRNewswire=연합뉴스) Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research - Dr. Shumpei Ishikawa and Translational Research - Dr. Hiromichi Ebi. The winners were honored with trophies and a monetary prize during the hybrid (virtual/live) meeting of the 80th Annual Meeting of the Japanese Cancer Association (JCA) on Saturday, October 2nd in Yokohama, Japan by Prof. Hideyuki Saya President of the JCA and Dr. Takato Noumi, Debiopharm's representative in Japan along with Thierry Mauvernay, President of Debiopharm, Bertrand Ducrey CEO of Debiopharm who joined virtually.
"Japan and Switzerland share several common values such as commitment to excellence and professional diligence. That's one of the reasons why I believe Japanese research continues to excel and surpass our expectations," expressed Thierry Mauvernay, president of Debiopharm. "It is our honor to award these two new JCA Mauvernay Award winners and realize what their early research could mean for patients in the future through further development."
"We were impressed with the potential implications of Dr.Ishikawa and Dr. Ebi in different cancer types. Cancer remains the leading cause of death worldwide so it deserves the deep exploration by great minds in order to come closer to a cure. Japanese cancer researchers continue to capture the attention of the international community as seen in several of the past Nobel Prizes in Medicine. So, we are very pleased to continue to this important award and hope to spark further collaboration," explained Bertrand Ducrey, CEO of Debiopharm.
Dr. Shumpei Ishikawa's disruptive research at the University of Toyko, is offering new insights into an aggressive form of gastric cancer, diffuse-type gastric carcinoma (DGC), by exploring the genomic characterization the cancer's life cycle. His comprehensive characterization of DGC includes the identification of genes that drive the transformation of cells to cancer cells (oncogenes), the molecular and cellular dissection of the tumor microenvironment and the environmental factors contributing to the disease. This holistic approach has led to several influential discoveries that have been published in top-ranking scientific journals.
Dr. Hiromichi Ebi's translational research at the Aichi Cancer Center Research Institute is examining the development of targeted therapies against tumor with aberrant MAPK signaling. His work is focusing on the elucidation of the molecular mechanisms underlying the differential clinical activities of drugs targeting mutated oncogenes depending on the cancerous tissue and the tumor microenvironment.
The JCA-Mauvernay Award
Since 2005, the Japanese Cancer Association (JCA) and Debiopharm Group have co-organized the 'JCA-Mauvernay Award'. This prize illustrates the curiosity that drives researchers as well as the scientific cooperation between Japan and Switzerland. It aims at recognizing outstanding achievements in the field of oncology amongst Japanese researchers, in both the fundamental and the clinical aspects. The award has a total value of CHF 25'000.
Debiopharm's commitment to patients
Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
Debiopharm Contact
Dawn Haughton-Bonine
Communication Manager
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
Source: Debiopharm International SA
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 9·19군사합의에 사실상 사망선고…확성기·전방훈련 족쇄 풀어 | 연합뉴스
- 동해 대형 석유전 올해 하반기부터 시추…내년 상반기 결과 나와(종합) | 연합뉴스
- 이원석, '김건희 여사 소환' 묻자 "법 앞에 예외도 성역도 없다" | 연합뉴스
- 의사 국가시험 '예정대로'…내년 의사공급 수천명 '펑크' 우려 | 연합뉴스
- 尹, 아프리카 10개국 정상과 릴레이회담…"맞춤형 협력 강화" | 연합뉴스
- 멕시코 헌정사 200년만 첫 여성 대통령 이정표 세웠다(종합2보) | 연합뉴스
- 길면 3년 소요…"경매차익으로 전세사기 피해지원, 신속성 관건" | 연합뉴스
- [르포] 섭씨 42도가 선선?…'불가마 폭염' 인도 뉴델리 시민들 만나보니 | 연합뉴스
- 사망 훈련병 동료들 "쓰러지기 전 건강 이상 보고한 적 없어"(종합) | 연합뉴스
- 공수처장 "채상병 사건 통화기록 확보 급해…빈틈 없도록 노력" | 연합뉴스